First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)

被引：0
|
作者：
Ravaud, A.
Oudard, S.
Gravis-Mescam, G.
Sevin, E.
Zanetta, S.
Theodore, C.
de Fromont, M.
Oukhatar, C. Mahier-Ait
Chene, G.
Escudier, B.
机构：
[1] CHU Bordeaux, Hosp St Andre, Bordeaux, France
[2] Hop Europeen Georges Pompidou, Paris, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Ctr Francois Baclesse, F-14021 Caen, France
[5] Ctr Georges Francois Leclerc, Dijon, France
[6] Hop Foch, Suresnes, France
[7] FNCLCC, Paris, France
[8] ISPED, Bordeaux, France
[9] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5146
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma
    Rini, B.
    Redman, B.
    Garcia, J. A.
    Burris, H. A., III
    Li, S.
    Fandi, A.
    Beck, R.
    Jungnelius, U.
    Infante, J. R.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1794 - 1799
  • [22] EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901)
    Davis, Ian D.
    Long, Anne
    Martin, Andrew
    Espinoza, David
    Yip, Sonia
    Kichenadasse, Ganessan
    Thompson, Jennifer F.
    Harrison, Michelle L.
    Lowenthal, Raymond M.
    Pavlakis, Nick
    Azad, Arun
    Kannourakis, George
    Steer, Christopher
    Goldstein, David
    Shapiro, Jeremy David
    Stockler, Martin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [23] EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
    Davis, Ian D.
    Gebski, Val
    Chatfield, Mark D.
    Grimison, Peter S.
    Kannourakis, George
    Boland, Amy L.
    Thompson, Jennifer
    Stockler, Martin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Multicenter prospective phase II study of sunitinib in non-clear cell type renal cell carcinoma
    Lee, J.
    Ahn, J.
    Lim, H.
    Lee, S.
    Kim, T.
    Lee, D.
    Cho, Y. M.
    Hong, J.
    Kim, C.
    Ahn, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] Immunomonitoring of a phase I/II study of AGS-003, a dendritic cell immunotherapeutic, as first-line treatment for metastatic renal cell carcinoma.
    Healey, D.
    Gamble, A. H.
    Amin, A.
    Cohen, V.
    Logan, T.
    Nicolette, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    Biagi, J. J.
    Oza, A. M.
    ChalChal, H. I.
    Grimshaw, R.
    Ellard, S. L.
    Lee, U.
    Hirte, H.
    Sederias, J.
    Ivy, S. P.
    Eisenhauer, E. A.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 335 - 340
  • [27] Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
    Flechon, A.
    Pouessel, D.
    Ferlay, C.
    Perol, D.
    Beuzeboc, P.
    Gravis, G.
    Joly, F.
    Oudard, S.
    Deplanque, G.
    Zanetta, S.
    Fargeot, P.
    Priou, F.
    Droz, J. P.
    Culine, S.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2476 - 2481
  • [28] Phase II evaluation of suramin in advanced renal cell carcinoma - A Southwest Oncology Group study
    Schroder, LE
    Lew, D
    Flanigan, RC
    Eisenberger, MA
    Seay, TE
    Hammond, N
    Needles, BM
    Crawford, ED
    UROLOGIC ONCOLOGY, 2001, 6 (04): : 145 - 148
  • [29] A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Reaume, M. Neil Neil
    Lalewski, Pawel
    Macfarlane, Robyn Jane
    MacKenzie, Mary J.
    Hotte, Sebastien J.
    Heng, Daniel Vick Chin
    Soulieres, Denis
    Miller, Jessie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Randomized phase II study of sunitinib+CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
    Hainsworth, John D.
    Mace, Joseph Ronald
    Reeves, James Andrew
    Crane, Edward J.
    Hamid, Oday
    Stille, John R.
    Flynt, Amy
    Polzer, John
    Milner, Alvin
    Roberson, Stephanie
    Arrowsmith, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345